Literature DB >> 26844728

Diagnosis of Epilepsy and Related Episodic Disorders.

Erik K St Louis, Gregory D Cascino.   

Abstract

PURPOSE OF REVIEW: This review identifies the diverse and variable clinical presentations associated with epilepsy that may create challenges in diagnosis and treatment. RECENT
FINDINGS: Epilepsy has recently been redefined as a disease characterized by one or more seizures with a relatively high recurrence risk (ie, 60% or greater likelihood). The implication of this definition for therapy is that antiepileptic drug therapy may be initiated following a first seizure in certain situations.EEG remains the most commonly used study in the evaluation of people with epilepsy. Routine EEG may assist in diagnosis, classification of seizure type(s), identification of treatment, and monitoring the efficacy of therapy. Video-EEG monitoring permits seizure classification, assessment of psychogenic nonepileptic seizures, and evaluation of candidacy for epilepsy surgery. MRI is pivotal in elucidating the etiology of the seizure disorder and in suggesting the localization of seizure onset.
SUMMARY: This article reviews the new International League Against Epilepsy practical clinical definition for epilepsy and the differential diagnosis of other physiologic paroxysmal spells, including syncope, parasomnias, transient ischemic attacks, and migraine, as well as psychogenic nonepileptic seizures. The initial investigational approaches to new-onset epilepsy are considered, including neuroimaging and neurophysiologic investigations with interictal and ictal video-EEG. Neurologists should maintain a high index of suspicion for epilepsy when children or adults present with a single paroxysmal spell or recurrent episodic events.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26844728     DOI: 10.1212/CON.0000000000000284

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  6 in total

1.  Reliability of reported peri-ictal behavior to identify psychogenic nonepileptic seizures.

Authors:  Wesley T Kerr; Andrea M Chau; Emily A Janio; Chelsea T Braesch; Justine M Le; Jessica M Hori; Akash B Patel; Norma L Gallardo; Janar Bauirjan; Corinne H Allas; Amir H Karimi; Eric S Hwang; Emily C Davis; Albert Buchard; David Torres-Barba; Shannon D'Ambrosio; Mona Al Banna; Andrew Y Cho; Jerome Engel; Mark S Cohen; John M Stern
Journal:  Seizure       Date:  2019-03-05       Impact factor: 3.184

2.  Serum prolactin level and lactate dehydrogenase activity in patients with epileptic and nonepileptic seizures: A cross-sectional study.

Authors:  Murat Yilmaz; Beliz Oztok Tekten
Journal:  Medicine (Baltimore)       Date:  2021-09-24       Impact factor: 1.817

3.  An objective score to identify psychogenic seizures based on age of onset and history.

Authors:  Wesley T Kerr; Emily A Janio; Chelsea T Braesch; Justine M Le; Jessica M Hori; Akash B Patel; Norma L Gallardo; Janar Bauirjan; Andrea M Chau; Eric S Hwang; Emily C Davis; Albert Buchard; David Torres-Barba; Shannon D'Ambrosio; Mona Al Banna; Andrew Y Cho; Jerome Engel; Mark S Cohen; John M Stern
Journal:  Epilepsy Behav       Date:  2018-02-02       Impact factor: 2.937

Review 4.  Sleep and Epilepsy: a Focused Review of Pathophysiology, Clinical Syndromes, Co-morbidities, and Therapy.

Authors:  J Layne Moore; Diego Z Carvalho; Erik K St Louis; Carl Bazil
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

5.  Electroencephalographic Abnormalities in the Screening for Pilot Applicants in Korea.

Authors:  Dan A Oh; Hyeyun Kim; Eun Kee Bae
Journal:  J Clin Neurol       Date:  2018-02-28       Impact factor: 3.077

6.  Reliability of additional reported seizure manifestations to identify dissociative seizures.

Authors:  Wesley T Kerr; Xingruo Zhang; Emily A Janio; Amir H Karimi; Corinne H Allas; Ishita Dubey; Siddhika S Sreenivasan; Janar Bauirjan; Shannon R D'Ambrosio; Mona Al Banna; Andrew Y Cho; Jerome Engel; Mark S Cohen; Jamie D Feusner; John M Stern
Journal:  Epilepsy Behav       Date:  2021-01-01       Impact factor: 2.937

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.